Literature DB >> 24326814

Avascular necrosis in sickle cell (homozygous S) patients: predictive clinical and laboratory indices.

A J Madu1, A K Madu, G K Umar, K Ibekwe, A Duru, A O Ugwu.   

Abstract

BACKGROUND: Pathogenetic mechanism as well as laboratory and clinical correlates of osteonecrosis in sickle cell have not been fully investigated. The aim of this study is to investigate the predictive value of the steady state white cell and platelet count as well as the frequency of bone pain crisis per annum to detect sickle cell patients who will eventually develop avascular necrosis (AVN). PATIENTS AND METHODS: A 5 year retrospective analysis of 122 homozygous S (HbSS) patients, aged 6-49 years (mean age 24.7 ± 7 years), out of which 16 patients (13.1%) had developed AVN within the years under review.
RESULTS: The prevalence of AVN in sickle cell patients was determined to be 13.1 per 1000. The steady state white cell count, platelet count, frequency of bone pain crisis and hematocrit, was compared in patients that develop AVN and those who had not over the period. Only the steady state platelet count was found to differ significantly ( P = 0.011) between these two patient groups and to correlate positively (Pearson correlation coefficient = -0.251) with development of AVN. The hematocrit, white cell count, and frequency of bone pain crisis were found neither to differ significantly nor correlate with the development of AVN.
CONCLUSION: In conclusion, patients with a raised steady state platelet count may have a higher tendency to develop AVN and may require closer orthopedic review and prophylactic intervention.

Entities:  

Mesh:

Year:  2014        PMID: 24326814     DOI: 10.4103/1119-3077.122852

Source DB:  PubMed          Journal:  Niger J Clin Pract            Impact factor:   0.968


  4 in total

1.  Clinical and Laboratory Predictors of Frequency of Painful Crises among Sickle Cell Anaemia Patients in Nigeria.

Authors:  Angela Ogechukwu Ugwu; Obike Godswill Ibegbulam; Theresa Ukamaka Nwagha; Anazoeze Jude Madu; Sunday Ocheni; Iheanyi Okpala
Journal:  J Clin Diagn Res       Date:  2017-06-01

2.  Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.

Authors:  Ademola Samson Adewoyin; Omokiniovo Sunday Oghuvwu; Omolade Augustina Awodu
Journal:  Afr Health Sci       Date:  2017-03       Impact factor: 0.927

3.  Sickle cell disease clinical phenotypes in Nigeria: A preliminary analysis of the Sickle Pan Africa Research Consortium Nigeria database.

Authors:  Hezekiah Isa; Samuel Adegoke; Anazoeze Madu; Abdul-Aziz Hassan; Chinatu Ohiaeri; Reuben Chianumba; Biobele Brown; Emmanuel Okocha; Ngozi Ugwu; Ijeoma Diaku-Akinwumi; Titilope Adeyemo; Aisha Kuliya-Gwarzo; Livingstone Dogara; Haliru Lawal; Yohanna Tanko; Adama Ladu; Umar Kangiwa; Lilian Ekwem; Seyi Oniyangi; Tambi Wakama; Domic Umoru; Olaniyi Olanrewaju; Norah Akinola; Uche Nnebe-Agumadu; Samuel Asala; Adekunle Adekile; John Olaniyi; Raphael Sangeda; Obiageli Nnodu
Journal:  Blood Cells Mol Dis       Date:  2020-04-23       Impact factor: 2.372

Review 4.  Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).

Authors:  Ademola Samson Adewoyin
Journal:  Anemia       Date:  2015-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.